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Abstract
Immune checkpoint blockade with anti-PD-1 antibodies is showing great promise for patients
with metastatic melanoma and other malignancies, but despite good responses by some
patients who achieve partial or complete regression, many others still do not respond. Here,
we sought peripheral blood T-cell biomarker candidates predicting treatment outcome in 75
stage IV melanoma patients treated with anti-PD-1 antibodies. We investigated associations
with clinical response, progression-free survival (PFS) and overall survival (OS). Univariate
analysis of potential biological confounders and known biomarkers, and a multivariate
model, was used to determine statistical independence of associations between candidate
biomarkers and clinical outcomes. We found that a lower than median frequency of periph-
eral PD-1+CD56+ T-cells was associated with longer OS (p = 0.004), PFS (p = 0.041) and
superior clinical benefit (p = 0.009). However, neither frequencies of CD56-CD4+ nor CD56-
CD8+ T-cells, nor of the PD-1+ fraction within the CD4 or CD8 subsets was associated with
clinical outcome. In a multivariate model with known confounders and biomarkers only the
M-category (HR, 3.11; p = 0.007) and the frequency of PD-1+CD56+ T-cells (HR, 2.39;
p = 0.028) were identified as independent predictive factors for clinical outcome under PD-1
blockade. Thus, a lower than median frequency of peripheral blood PD-1+CD56+ T-cells
prior to starting anti-PD-1 checkpoint blockade is associated with superior clinical response,
longer PFS and OS of stage IV melanoma patients.
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Introduction
Recent innovations in cancer treatment have led to great success in late-stage melanoma[1,2].
The first FDA/EMA-approved checkpoint inhibitor, the monoclonal antibody ipilimumab
against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) expressed on the surface of T-
cells, and antagonistic antibodies targeting programmed death-1 (PD-1), such as nivolumab
and pembrolizumab, yielded an improvement in response rates, progression-free survival
(PFS) and overall survival (OS) in patients with advanced melanoma[3–5]. Although a propor-
tion of patients responds to these agents and benefits from long-lasting remissions, there are
many non-responding patients who may nonetheless suffer side effects[6]. Therefore, the
search for biomarkers indicative of a response to a certain treatment and predicting the out-
come and potential associated toxicity is of importance. The source of material for such assays
ideally needs to be easy and fast to access, guaranteeing later clinical workability. Peripheral
blood fulfills these requirements and is currently the source of the only validated biomarker in
late-stage melanoma in routine use, namely serum lactate dehydrogenase (LDH) levels[7].
Recent studies revealed several potential biomarker candidates associating with outcome of
immune checkpoint therapy in metastatic melanoma, such as the frequencies of peripheral
blood myeloid-derived suppressor cells (MDSCs) and defined T-cell subsets in patients treated
with ipilimumab[8–10]. More recently in patients treated with anti-PD-1 antibodies, frequen-
cies of classical monocytes in the periphery[11] or a reinvigoration of circulating exhausted,
Ki65+PD-1+CD8+ T-cells in conjunction with tumor burden were recently suggested as mea-
sures to predict poor clinical responses[12].
In addition to the well-documented CD4+ and CD8+ T-cell subsets, another peripheral
subset of T-cells, expressing the neural cell adhesion molecule 1 (NCAM1; CD56), commonly
expressed on group I innate lymphoid NK-cells[13,14], has been relatively poorly investigated
in the context of melanoma immunotherapy. This CD56+ T-cell population represents a phe-
notypically and functionally heterogeneous population, divided into type I[15,16] and type II
[17,18] Natural Killer T (NKT) cells. Further, CD56 expression on CD8+ and CD4-CD8- T-
cells can be induced by TCR-mediated activation, resulting in poor proliferative capacity but
enhanced cytotoxicity[19]. However, additional T-cell populations, such as γδ T-cells[20,21]
and regulatory T-cells (Tregs)[22] can also express CD56. In cancer, higher frequencies of this
heterogeneous population and functional impairments thereof relative to healthy controls
have been reported[23–25]. However, there is also evidence that peripheral CD56+ T-cell fre-
quencies might be affected by other diseases such as psoriasis[26], vitiligo[27] and viral infec-
tions like human cytomegalovirus (CMV)[28] and chronic Hepatitis B[29].
The aim of the present study was to investigate peripheral CD56+ T-cell populations and
the therapeutically relevant PD-1+ fraction thereof in stage IV melanoma before the initiation
of PD-1 immune checkpoint therapy. Correlations with clinical meta-data such as serum
LDH-levels, M-category, response evaluation according to Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.1[30], PFS and OS were performed to evaluate this T-cell
subpopulation as a novel biomarker-candidate for outcome of PD-1 immune blockade.
Materials and methods
Patients
Patients’ blood samples were obtained between March 2015 and March 2017 from three differ-
ent clinical centers: Tu¨bingen, Dresden, Lu¨beck. Sample size calculation using nQuery Advisor
revealed that at least 68 patients were required to identify a biomarker with clinical relevance
(improvement in one-year OS), when the observed cohort is dichotomized by the latter in two
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balanced groups (equal n). Clinical relevance was defined as 80% one-year OS rate in the
favorable and 60% in the unfavorable group considering α = 0.05 and a power of 80%
(1-sided). The total sample size for this study was set to 75 patients, assuming a drop-out rate
of 10%. All 75 included patients had stage IV melanoma with distant metastases, received no
previous PD-1 immune checkpoint blockade and donated blood just before starting therapy
with anti-PD-1 antibodies. Patients received either 2-3mg/kg Pembrolizumab every 3 weeks or
3mg/kg Nivolumab every 2 weeks. Within 24 hours of blood draw, peripheral blood mononu-
clear cells (PBMCs) were centrally isolated in Tu¨bingen using Ficoll-Hypaque density gradient
centrifugation and were immediately cryopreserved. Anti CMV-specific antibody screening
was performed using Cobas 6000 / Cobas e 601 analyzer with quantitative Elecsys CMV IgG
(U/ml) assays (Roche diagnostics). Relevant clinical metadata were documented for each
patient. All patients gave written informed consent for biobanking and use of biomaterial and
clinical data for scientific purposes. This study and experimental procedures were approved by
the local Tu¨bingen Ethics Committee (490/2014BO1 and 792/2016BO2). The anonymized raw
dataset is summarized in S1 Table.
Flow cytometry
Cryopreserved PBMCs were thawed and 1x106 cells per sample washed with PBS containing
2% FCS, 2 mM EDTA, and 0.01% sodium azide at room temperature. After Fc receptor
blocking with Gamunex (human immunoglobulin; GRIFOLS) and labeling of dead cells with
ethidium monoazide (EMA; Biotinum), the cells were stained with the following titrated
monoclonal antibodies: CD3-A700 (clone UCHT1, Biolegend), CD56-FITC (clone HCD56,
Biolegend), CD4-PerCP (clone SK3, BD Bioscience), CD8-APC-Cy7 (clone SK1, Biolegend)
and PD-1-BV711 (clone EH12.2H7, Biolegend). Lastly, after additional washing the samples
were measured with a LSRII cytometer (BD) and processed with BD FACSDiva software 6.1.3.
Single color controls were used for automatically calculated compensation.
Flow cytometry data analysis
The analysis of the resulting flow cytometry data was performed using Flowjo 10.4 (Treestar).
An example of the applied gating strategy is displayed in S1 Fig. To monitor potential inter-
batch discrepancies, one sample deriving from the same large standard batch of PBMCs from
a healthy subject was included in each patient sample run (day of measurement). After setting
a time gate to identify potential fluctuations in the flow rate and an FSC-A versus FCC-H and
an SSC-A versus SSC-H gate to exclude debris, duplicates and dead cells were excluded (i.e.
ethidium monoazide bromide [EMA]-positive events). Within viable and morphologically-
gated lymphocytes (SSC-A versus FSC-A) the CD56+CD3+ and CD56-CD3+ T-cells were
selected and further subdivided into CD8+, CD4+ and double-negative (DN) T-cells. All pop-
ulations were characterized for PD-1 expression. A threshold of minimally 120 processed
events was set as cut-off population size for subdivision in daughter populations.
Statistical data analysis
Throughout this work,�median frequency of the cell population of interest was used as cutoff
to dichotomize the cohort for survival correlations. OS was defined from the first dose of
antagonistic PD-1 antibodies to either the death of a patient due to disease or to the date of last
contact. Deaths for other reasons were considered as censored events. Survival probabilities
were estimated by the Kaplan-Meier approach and compared by log-rank testing. PFS was
defined as the time from the date of starting therapy to the date of progression or death. Ele-
vated/normal serum LDH was determined by the actual value in relation to the upper limit of
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normal. A stepwise Cox regression analysis with backward variable selection based on p-values
was performed to determine the relative impact of single predictive features. Results of the
Cox regression analysis are described by means of hazard ratios (HR), and p-values (Wald
test). Patients with missing values for at least one feature were excluded.
Response to therapy was evaluated by local physicians at the respective centers following
the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1[30] and was catego-
rized as complete response (CR), partial response (PR), stable disease (SD) or progressive
disease (PD). We defined clinical response to therapy as best overall response between the ini-
tiation of therapy and progression, or start of a new systemic therapy, considering all available
tumor assessments within this period of time. Clinical benefit analysis included patients
experiencing CR, PR and SD contrasted with patients suffering PD. Fisher’s exact test (two-
sided) was used to evaluate the significance of differences of these correlations.
T-distributed stochastic neighbor embedding (tSNE) analysis was used to visualize the
composition of the heterogeneous CD56+ T-cell subset and its PD-1 expression pattern using
FlowJo and the embedded tSNE approach[31]. Prior to application of the latter, all CD56+ T-
cells of each patient were extracted from the raw data files (fcs-format), down-sampled (using
the respective tool in the FlowJo software) and transferred into new fcs-files, that were used for
downstream analysis. Expression of CD4 and CD8 was the basis for the clustering. The same
gating strategy as described above was used to visualize the presence/absence of CD4, CD8
and PD-1 on the respective tSNE plot.
The Mann-Whitney U test was used for group-wise comparisons, while the Kruskal-Wallis
test was used for statistical evaluation of groups with n>2. P values <0.05 were considered sig-
nificant throughout the study. SPSS 24 and Prism 6 (GraphPad) were used for statistical
calculations.
Results
Patients and treatments
Cryopreserved PBMCs from 75 stage IV melanoma patients prior to infusion of antagonistic
PD-1 antibodies (pembrolizumab (n = 70) or nivolumab (n = 5)) were provided by three clini-
cal centers (Table 1). Of these 75 patients, 45 were male (60%), 53 were CMV-IgG seropositive
(70.7%) and the median age was 73 years (interquartile-range 62 to 79 years). Clinical response
was assessed following the Response Evaluation Criteria in Solid Tumors (RECIST) version
1.1[30]. Best overall response was defined as best clinical response between the initiation of
PD-1 immune checkpoint therapy and progression, or start of a new systemic treatment:
Twelve patients experienced CR (16%), 9 PR (12%), 12 SD (16%) and 42 patients had PD
(56%). The M-category was defined according to the American Joint Committee on Cancer
(AJCC) recommendations[32]. Fifteen patients were classified as M1a (20%), 19 patients were
M1b (25.3%) and 35 patients M1c (46.7%). Six patients could not be classified. Details are sum-
marized in Table 1. Median survival of the cohort was not reached, the median PFS was 128
days and the median follow up was nearly two years (709 days).
T-cell profiling
The peripheral CD3+ T-cell compartment was divided into the following major phenotypes:
CD56-CD4+, CD56-CD8+, CD56-CD4-CD8-(DN) and CD56+ (S1 Fig). The largest periph-
eral T-cell phenotype according to frequency was CD56-CD4+ with a median of 68.8% of all
CD3+ T-cells. The second most common was CD56-CD8+ with 19.7% in median, whereas
CD56-DN cells were present at a median frequency of only 4.1%. An even smaller proportion
of all CD3+ T-cells was CD56+ (median 2.7%, Fig 1A). However, this CD56+ T-cell
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population contained the largest proportion of PD-1+ cells (median frequency of 16.6%) rela-
tive to all the other T-cell populations (i.e. medians of 12.7% of CD56-CD8+, 8.3% of
CD56-CD4+ and 4.5% of CD56-DN T-cell subset, Fig 1B). Of note, frequencies of the PD-1+
T-cells did not correlate with frequencies of the parental T-cell populations.
All patients were serotyped to determine anti-CMV specific IgG titers indicative of a latent
infection with CMV. The latter is known to have a profound impact on the distribution of
peripheral T-cell phenotypes. For this reason, it is included here as a potential confounding
factor for the analysis of tumor-associated immune cell marker patterns[28,33]. In accordance
with previous reports in healthy controls, CMV-seropositive patients possessed significantly
higher frequencies of CD8+ T cells (23.4% versus 17.4% median; p = 0.033), lower frequencies
of CD4+ T cells (69.7% versus 77% median; p = 0.005) and a greater abundance of CD56+ T
cells (3.1% versus 1.2% median; p� 0.001) relative to CMV-seronegative patients (S2A Fig)
[28,33]. However, CMV-seropositivity had no significant impact on the abundance of any of
the PD-1+ T-cell subsets analyzed here (S2B Fig).
Correlation of T-cell subsets with survival and response
Correlations of OS with frequencies of the major peripheral blood phenotypes CD56-CD4+,
CD56-CD8+, CD56-DN and CD56+ T-cells among all CD3+ T-cells did not reveal any statis-
tically significant associations (Table 2). Next, we quantified the proportions of these 4 T-cell
populations expressing PD-1. None of the observed PD-1+ T-cell phenotypes was informative
Table 1. Cohort characteristics.
Variable Category Patients n Patients %
Sex Male 45 60
Female 30 40
Age �60 17 22.7
>60 16 21.3
>70 25 33.3
>80 17 22.7
Median age 73 years
Treatment Pembrolizumab 70 93.3
Nivolumab 5 6.7
Center Tu¨bingen 55 73.3
Dresden 13 17.3
Lu¨beck 7 9.3
M-category M1a 15 20
M1b 19 25.3
M1c 35 46.7
unknown 6 8
CMV serostatus Seropositive 53 70.7
Seronegative 21 28
unknown 1 1.3
Serum LDH normal 51 68
elevated 24 32
Best clinical response (RECIST) CR 12 16
PR 9 12
SD 12 16
PD 42 56
https://doi.org/10.1371/journal.pone.0221301.t001
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for outcome after immune checkpoint therapy, except the abundance of PD-1+ T-cells within
the CD56+ T-cell population. The frequency of these cells correlated negatively with OS when
dichotomized by median frequency (p = 0.004; Fig 2A). Thus, patients with>16.6% of circu-
lating PD-1+CD56+ T-cells had a 1-year OS rate of 52.8% (19 of 36), while patients in the
reciprocal group (�16.6%) had a 1-year OS rate of 78.4% (29 of 37). Patients in the group with
superior OS also had a significantly longer PFS than the reciprocal group (p = 0.041; S3 Fig).
The 1-year PFS-rate was only 27.8% (10 of 36) in the group of patients defined through high
frequencies of PD-1+CD56+ T-cells, compared to 35.1% for those in the reciprocal group (13
of 37). Next, we investigated whether the PD-1+CD56+ T-cell population also correlated with
clinical response to PD-1 immune checkpoint therapy and found that 59.5% of patients in the
group with a low frequency of PD-1+CD56+ T-cells (�16.6%) (22 of 37) experienced a benefit
(CR, PR or SD) in contrast to only 27.8% patients (10 of 36) in the reciprocal group (p = 0.009)
(Fig 2B).
Fig 1. Peripheral T-cell profile. Frequencies of CD56- CD4+, CD8+, DN and CD56+ T-cell subsets (n = 75 for all) in the
CD3+ T-cell population (A) and the PD-1+ fraction within these subsets (B) in melanoma patients prior to initiation of
immune therapy using antagonistic PD-1 antibodies. Two samples could not be analyzed for the PD-1+ fraction within
the CD56+ T-cells. Lines in the dot plots indicate the population median and each dot represents an individual patient;
��� p< 0.001 using the Kruskal-Wallis test.
https://doi.org/10.1371/journal.pone.0221301.g001
Table 2. Univariate T-cell phenotype OS analysis.
Variable Total n Categories n %dead 1-year survival rate n (%) P-value
CD4+ CD56- T-cells 75 �68.8 39 38.5 28 (71.8) 0.245
>68.8 36 50 22 (61.1)
CD8+ CD56- T-cells 75 �19.7 38 52.6 22 (57.9) 0.085
>19.7 37 35.1 28 (75.7)
CD4-CD8- CD56- T-cells 75 �4.1 38 44.7 25 (65.8) 0.961
>4.1 37 46.8 25 (67.6)
CD56+ T-cells 75 �2.7 40 42.5 27 (67.5) 0.677
>2.7 35 45.7 23 (65.7)
https://doi.org/10.1371/journal.pone.0221301.t002
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Investigation of dependencies between PD-1+CD56+ T-cells and other
potentially confounding features for associations with OS
To further investigate the predictive capacity of peripheral PD-1+CD56+ T-cell frequencies
for effective PD-1 immune checkpoint therapy, we ran a descriptive, step-wise multivariate
analysis that combined this variable with the M-category (M1a/b versus M1c), serum LDH
(normal versus elevated); CMV-serostatus, sex, age (�73 versus>73), PD-1+CD4+ T-cells
(�8.3% versus>8.3%), and PD-1+CD8+ T-cells (�12.7% versus >12.7%). This analysis
included 68 patients, for which all variables were available, while 7 patients were excluded
because at least one parameter was missing. Interestingly, univariate analysis of these features
identified only the M-category and PD-1+CD56+ T-cells as correlating with OS (p = 0.005;
p = 0.004, respectively; S4 Fig). Moreover, multivariate analysis identified the PD-1+CD56+
frequencies (HR, 2.39; p = 0.028) and the M-category (HR, 3.11; p = 0.007) as independent
predictive features for outcome under PD-1 immune checkpoint therapy. The combination of
these two independent predictive features allows the identification of two extreme groups:
very poor (M1c plus > 16.6% peripheral PD-1+CD56+ T-cells) and superior survivors (M1a/b
plus�16.6% peripheral PD-1+CD56+ T-cells) (OS p� 0.001; PFS = 0.030; clinical benefit 3 of
18 versus 11 of 18 p = 0.006; Fig 3).
Composition of the peripheral CD56+ T-cell population
Finally, we analyzed the composition of the heterogeneous CD56+ T-cell population using the
t-distributed stochastic neighbor embedding algorithm (tSNE)[31] on the entire data set
(n = 73). The CD56+ T-cell population consisted of a median of 40.3% CD8+, 16.4% CD4+,
Fig 2. Peripheral PD-1+CD56+ T-cell frequencies correlate with clinical outcome after therapy. Probability of overall survival among patients with>16.6%
[blue] and�16.6% [green] peripheral PD-1+CD56+ T-cell frequencies prior to the start of therapy were analyzed using the Kaplan Meier approach (p = 0.004; log-
rank test) (A). Vertical lines indicate censored events. The number of patients that experienced a clinical benefit from therapy (complete responder, partial
responder or stable disease) with either>16.6% (blue) or�16.6% (green) PD-1+CD56+ T-cell frequencies are displayed in (B) (�� p� 0.01; Fisher’s exact test, two-
sided).
https://doi.org/10.1371/journal.pone.0221301.g002
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28.6% DN and 3.8% CD4+CD8+ (DP) cells (Fig 4A). The tSNE map presented in Fig 4B is uti-
lized to visualize the distribution of PD-1 expression on all CD56+ T-cells. The latter was
found on all four subsets of the CD56+ T-cell population (Fig 4B), suggesting that it is the
expression of CD56 itself regardless of which type of T-cell expresses it (i.e. not the compart-
mentalization of T-cells by presence/absence of CD4 and/or CD8) that should be considered
when searching for direct targets of PD-1 immune checkpoint therapy.
Discussion
Earlier work has identified peripheral immune cell populations such as MDSCs or effector T-
cell phenotypes as promising biomarker candidates for the clinical outcome of anti-CTLA4
checkpoint blockade in metastatic melanoma[8–10]. However, different biomarker-candidates
have been recently suggested for correlations with outcome for PD-1 immune checkpoint
therapy. For example, frequencies of classical monocytes[11], reinvigoration of a circulating
exhausted T-cell population in conjunction with pre-treatment tumor burden[12] or a distinct
activated tumor-resident effector memory T-cell population[34] were reported to be informa-
tive for outcome of PD-1 immune checkpoint therapy in late stage melanoma.
The focus of the present biomarker discovery study in stage IV melanoma was the investi-
gation of T-cell populations in patients receiving PD-1 immune checkpoint therapy. We per-
formed a detailed analysis of circulating T-cell subsets, including unconventional CD56+ T-
cells, and their PD-1+ fraction prior to the infusion of antagonistic PD-1 antibodies. We iden-
tified a strong inverse correlation of peripheral frequencies of PD-1+CD56+ T-cells before the
start of PD-1 immune checkpoint therapy with clinical benefit, PFS and OS. Moreover, this
population contained the highest frequency of PD-1+ T-cells compared to all observed T-cell
Fig 3. Combinatory model. The combinatory model comprising the predictive capacity of two independent predictive features: peripheral PD-1+CD56+ T-cell
frequencies and the M-category. Superior survivors (green) are characterized by low abundance of PD-1+CD56+ T-cells and grouping in M1a/b. Reciprocally,
patients with high frequencies of PD-1+CD56+ T-cells and grouping in the M1c category (black) had the poorest outcome (A). Vertical lines indicate censored
events in the Kaplan Meier plot. Analysis of clinical benefit from PD-1 immune checkpoint therapy is shown accordantly with absolute numbers of patients with
clinical benefit in these groups in (B) (� p�0.05; �� p� 0.01). Statistical evaluation was performed by two-sided Fisher exact test.
https://doi.org/10.1371/journal.pone.0221301.g003
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populations and is thereby likely to be a prominent target of the applied therapy. Thus, our
data identify a promising predictive biomarker candidate for response to and outcome after
anti-PD-1 immune checkpoint blockade.
PD-1 is upregulated on T-cells in response to antigen exposure and is of particular interest
for the identification of cancer antigen-reactive peripheral and tumor-infiltrating CD8+ T-cell
populations in melanoma[35–37]. However, we identified neither correlations between fre-
quencies of classical circulating CD4+ or CD8+ T-cells lacking CD56 expression, nor their
PD-1+ fractions with outcome after therapy, although these populations may contain tumor-
reactive cells[35,38]. In contrast to the latter, little is known about the heterogeneous CD56+
T-cell populations and their PD-1-positivity in human cancer. CD56+ T cells consist mainly of
type I[15,16] and II[17,18] NKT-cells and certain other, non-MHC-restricted T-cells such as
γδ T-cells[20,22], and are commonly described as immune invigorating cells including those
producing T helper 1 cytokines and mediating efficient cytotoxicity[39]. The latter might be
impaired in cancer: frequencies of CD56+ T-cells in AML and ALL patients achieving remis-
sion on chemotherapy returned to those in healthy controls, although their functionality was
still impaired[24]. Interestingly Achberger et. al found changes in the phenotypic composition
of circulating CD56+ T-cells in primary uveal melanoma. Development of metastasis was
associated with a decrease of peripheral DN and CD8+CD56+ T-cells, whereas the frequency
of CD4+CD56+ T-cells was not altered, suggesting a potential involvement of DN and
CD8+CD56+ T-cells in cancer immunosurveillance in uveal melanoma[40]. CD4 and/or CD8
is differently expressed on type I or type II NKT-cells[15–18] or even on γδ T-cells[21] and
might be used to conclude associations between identified phenotypes and functional
Fig 4. Composition and PD-1 expression of the CD56+ T-cell population. The composition of the CD56+ T-cell population is visualized in a tSNE map that
comprises all samples of the observed cohort. Clustering based on CD4 and CD8 expression visualized the 4 different subsets (CD8 in blue, CD4 in red, double
positive in green and double negative in orange) (A). PD-1 expression is highlighted in red (B). Each dot in the maps represents a single cell and its color the
phenotype based on manual gating.
https://doi.org/10.1371/journal.pone.0221301.g004
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capabilities. However, the here identified relevance of PD-1+CD56+ T-cells prior to the
initiation of PD-1 blockade was not linked with the presence/absence of CD4 and/or CD8 as
visualized in an unbiased tSNE analysis approach. Further investigation on the basis of this
approach was not performed due to limitations of the algorithm when run on polychromatic
flow cytometry data.
Tumor infiltration by CD56+ T-cells has been associated with cancer rejection[39,41,42].
For example, high tumor infiltration rates of CD56+ T-cells correlated in gastric cancer with
prolonged OS, while their PD-1 expression levels did not differ compared to non-tumor tissue
resident cells[43]. But not every CD56+ T-cell acts in an immune stimulatory manner. Immu-
nosuppressive capabilities of these cells in the tumor microenvironment have also been
reported[22,44]. However, the here revealed negative associations between high peripheral
PD-1+CD56+ T-cell frequencies and the course of disease does not allow a final conclusion as
to whether the mechanistic contribution of these cells in the ensemble of immune-mediated
cancer rejection under anti-PD-1 immune therapy is positive or negative. This functional anal-
ysis remains to be performed in future studies.
Nonetheless, we considered in this study major potential confounding features that might
impact T-cell immunomonitoring to achieve best statistical accuracy[45,46]. Seropositivity for
human herpesvirus V (Cytomegalovirus, CMV)[28,33] has a well-documented impact on T
cell subset distributions. For the first time, to the best of our knowledge, CMV-IgG seropositiv-
ity was considered in a T-cell immunomonitoring study of melanoma patients under immune
checkpoint therapy. Subset analysis of our cohort revealed lower CD4+ and higher CD8+ and
CD56+ T-cell frequencies in CMV-seropositive than in -seronegative patients, consistent with
observations in healthy elderly subjects[28]. However, CMV seropositivity had, despite
increasing the heterogeneity within the T-cell subsets, no significant impact on clinical out-
come after PD-1 blockade. We also found no correlation of the former with sex or age. Fur-
ther, a descriptive, stepwise multivariate analysis to determine dependencies between this
biomarker candidate and other potentially informative features identified the abundance of
PD-1+CD56+ T-cells as the only independent predictor of patients’ OS apart from the M
category.
Thus, we have identified a strong biomarker candidate for clinical outcome after PD-1
immune checkpoint therapy based on the frequency of PD-1+CD56+ T-cells in peripheral
blood. Confirmation and validation of these findings is required in future studies. Further,
comparative investigation of these cells and the PD-1 expression intensity, as recently reported
[47], in corresponding tumor tissue and peripheral blood samples of melanoma patients
and healthy donors will be warranted to learn more about potential migration patterns, func-
tional and phenotypical characteristics and could help to understand why patients with low
PD-1+CD56+ T-cell frequencies have better chances of benefiting from therapy.
Supporting information
S1 Fig. Gating strategy for the flow cytometry-based analysis of CD56+ and CD56- T-cell
populations. Here, we display a representative data set from one patient to illustrate the flow
cytometry gating strategy. The first plot shows the SSC-A channel versus measured time to
monitor unexpected alterations in the pressure system of the LSR II (BD) flow cytometer.
Next, debris (SSC-A versus FSC-A) and duplicates (FSC-A versus FSC-H and SSC-A versus
SSC-H) were excluded. Viable cells were selected by excluding EMA-positive cells (EMA
versus FSC-A). A morphological gate was used to select the lymphocyte population (SSC-A
versus FSC-A). The thus selected lymphocyte population was divided into CD56+CD3+ and
CD56-CD3+ cells. These T-cells were further separated into CD4+, CD8+, CD4-CD8- and
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CD4+CD8+ T-cells. Finally, the frequencies of PD-1+ fractions on the selected T-cell subsets
were determined.
(PDF)
S2 Fig. Impact of CMV seropositivity on the observed peripheral T-cell compartment. The
frequency of CD56- and CD56+ T-cell populations (A) and the frequencies of the PD-1+ frac-
tion within these populations (B) are compared between CMV seronegative (CMV-, n = 21)
and seropositive (CMV+, n = 53) melanoma patients. Horizontal lines in each plot show the
median and each symbol represents an individual patient; � p� 0.05, �� p� 0.01, ��� p<
0.001, using the Mann-Whitney-U-test.
(PDF)
S3 Fig. Correlation of the peripheral PD-1+CD56+ T-cell subset with progression-free sur-
vival (PFS). Stratification of the patient cohort according to PD-1+CD56+ T-cell frequencies
(�16.6% [green]; >16.6% [blue] PD-1+CD56+ T-cells) reveals a significant correlation of the
frequencies of these cells with PFS (p = 0.041, log-rank test) using the Kaplan-Meier method.
Vertical lines indicate censored events.
(PDF)
S4 Fig. Univariate analysis of correlations between variables and OS. Stratification of the
cohort according to the following features: PD-1+CD4+ T-cells, PD-1+CD8+ T-cells, serum
LDH, M-category, sex, age and CMV-serostatus for associations with patient survival using
the Kaplan-Meier method. Vertical lines indicate censored events and p-values were estimated
by log-rank testing.
(PDF)
S1 Table. Anonymized raw dataset.
(CSV)
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